|
(MoneyNewsWire.Net, April 27, 2018 ) The global PDX models market is expected to reach USD 167.6 Million by 2022 from USD 77.4 Million in 2017, at a CAGR of 16.7%. The growth of this market is majorly driven by the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. However, the high cost of personalized PDX models and stringent guidelines regarding the ethical use of animals in cancer research are expected to restrain the growth of this market during the forecast period.
Explore More Information about report @ https://www.researchcosmos.com/reports/global-patient-derived-xenograft-pdx-models-market-analysis-and-forecast-to-2022-growth-opportunit/4423191
The report analyzes the patient derived xenograft models market by type, tumor type, application, end user, and region. On the basis of type, the market is segmented into mice and rat models. The mice models segment is estimated to command the largest share of the global market in 2017. The rat models segment, on the other hand, is projected to register the highest CAGR from 2017 to 2022. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. The development of immunodeficient rats will drive the usage of rat models in PDX model generation. Based on tumor type, the PDX models market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the gastrointestinal tumor models segment is expected to account for the largest share of the global market.
Request free sample @ https://www.researchcosmos.com/request/4423191
Based on application, the PDX models market has been broadly segmented into preclinical drug development & basic cancer research and biomarker analysis. In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global patient derived xenograft models market. Growth in this segment is mainly driven by the increasing number of research activities in the field of oncology drug research. On the basis of end user, the PDX models market has been segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic & research institutions. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the patient derived xenograft models market in 2017. The large share of this segment is due to the increasing expenditure on R&D by companies for drug development.
Geographically, in 2017, North America is estimated to account for the largest share of the global PDX models market, followed by Europe. Growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada are the major factors expected to drive the growth of the market during the forecast period.
The various players in the patient derived xenograft models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).
Check for discount @ https://www.researchcosmos.com/discount/4423191
About Us:
Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on gamut of sectors across the globe. We’re associated with world renowned publishers who when combined, serve hundreds of fortune listed companies and publish wide range of insightful reports which cover nook and corner of every industry vertical.
Research Cosmos
Dani Rodriguez
+1 888 709 8757
dani@researchcosmos.com
Source: EmailWire.Com 
|
